[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SI2794905T1 - Modificirani polipeptidi za ogrodja bispecifičnega protitelesa - Google Patents

Modificirani polipeptidi za ogrodja bispecifičnega protitelesa

Info

Publication number
SI2794905T1
SI2794905T1 SI201231794T SI201231794T SI2794905T1 SI 2794905 T1 SI2794905 T1 SI 2794905T1 SI 201231794 T SI201231794 T SI 201231794T SI 201231794 T SI201231794 T SI 201231794T SI 2794905 T1 SI2794905 T1 SI 2794905T1
Authority
SI
Slovenia
Prior art keywords
bispecific antibody
modified polypeptides
antibody backbones
backbones
polypeptides
Prior art date
Application number
SI201231794T
Other languages
English (en)
Inventor
Partha S. Chowdhury
Vaheh Oganesyan
Yariv Mazor
Nazzareno Dimasi
Original Assignee
Medimmune, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune, Llc filed Critical Medimmune, Llc
Publication of SI2794905T1 publication Critical patent/SI2794905T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SI201231794T 2011-12-20 2012-12-18 Modificirani polipeptidi za ogrodja bispecifičnega protitelesa SI2794905T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161577956P 2011-12-20 2011-12-20
EP12860127.5A EP2794905B1 (en) 2011-12-20 2012-12-18 Modified polypeptides for bispecific antibody scaffolds
PCT/US2012/070310 WO2013096291A2 (en) 2011-12-20 2012-12-18 Modified polypeptides for bispecific antibody scaffolds

Publications (1)

Publication Number Publication Date
SI2794905T1 true SI2794905T1 (sl) 2020-08-31

Family

ID=48669692

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201231794T SI2794905T1 (sl) 2011-12-20 2012-12-18 Modificirani polipeptidi za ogrodja bispecifičnega protitelesa

Country Status (19)

Country Link
US (1) US9527927B2 (sl)
EP (1) EP2794905B1 (sl)
JP (1) JP6541974B2 (sl)
CN (1) CN104011221B (sl)
AU (1) AU2012355415B2 (sl)
CA (1) CA2859667C (sl)
CY (1) CY1123079T1 (sl)
DK (1) DK2794905T3 (sl)
ES (1) ES2816078T3 (sl)
HK (1) HK1203560A1 (sl)
HR (1) HRP20201004T1 (sl)
HU (1) HUE049457T2 (sl)
LT (1) LT2794905T (sl)
PL (1) PL2794905T3 (sl)
PT (1) PT2794905T (sl)
RS (1) RS60499B1 (sl)
SI (1) SI2794905T1 (sl)
SM (1) SMT202000342T1 (sl)
WO (1) WO2013096291A2 (sl)

Families Citing this family (292)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
KR101456326B1 (ko) 2009-04-07 2014-11-12 로슈 글리카트 아게 3가, 이중특이적 항체
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
RU2015153109A (ru) 2009-09-16 2019-01-15 Дженентек, Инк. Содержащие суперспираль и/или привязку белковые комплексы и их применения
AR080793A1 (es) 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
EP2635607B1 (en) 2010-11-05 2019-09-04 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
HUE038305T2 (hu) 2010-11-17 2018-10-29 Chugai Pharmaceutical Co Ltd A VIII vérkoagulációs faktor mûködésére alternatív funkciójú multispecifikus antigén-kötõ molekula
ES2549638T3 (es) 2011-02-28 2015-10-30 F. Hoffmann-La Roche Ag Proteínas de unión a antígeno
KR101572338B1 (ko) 2011-02-28 2015-11-26 에프. 호프만-라 로슈 아게 1가 항원 결합 단백질
CN103889452B (zh) 2011-08-23 2017-11-03 罗切格利卡特公司 对t细胞活化性抗原和肿瘤抗原特异性的双特异性抗体及使用方法
CN109897103B (zh) 2011-11-04 2024-05-17 酵活英属哥伦比亚有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
BR112014018575A2 (pt) 2012-01-26 2017-07-04 Amgen Inc polipetídeos de fator de diferenciação de crescimento 15 (gdf-15)
GB201203051D0 (en) * 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201203071D0 (en) * 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
WO2014055784A1 (en) 2012-10-03 2014-04-10 Zymeworks Inc. Methods of quantitating heavy and light chain polypeptide pairs
RU2015117393A (ru) 2012-10-08 2016-12-10 Роше Гликарт Аг Лишенные fc антитела, содержащие два Fab-фрагмента, и способы их применения
CA2890575C (en) 2012-11-05 2021-11-09 Jumpei Enami Antibody and antibody composition production method
EP2917360B1 (en) 2012-11-06 2020-01-08 Medlmmune, LLC Antibodies to s. aureus surface determinants
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
US10077298B2 (en) * 2012-11-28 2018-09-18 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
HUE054443T2 (hu) * 2013-02-08 2021-09-28 Novartis Ag Ellenanyagok módosítására, ezáltal immunkonjugátumok elõállítására szolgáló specifikus helyek
LT2961771T (lt) 2013-02-26 2020-03-10 Roche Glycart Ag Bispecifinės t ląstelę aktyvinančios antigeną surišančios molekulės, specifinės cd3 ir cea antigenams
EP3444278A1 (en) 2013-02-26 2019-02-20 Roche Glycart AG Bispecific t cell activating antigen binding molecules
KR20160003803A (ko) 2013-04-29 2016-01-11 에프. 호프만-라 로슈 아게 FcRn 결합이 제거된 항-IGF-1R 항체 및 혈관 눈 질환의 치료에 있어서 이의 용도
KR102282134B1 (ko) 2013-04-29 2021-07-27 에프. 호프만-라 로슈 아게 인간 fcrn-결합 변형된 항체 및 사용 방법
CN105164157B (zh) 2013-04-29 2024-05-28 豪夫迈·罗氏有限公司 Fc-受体结合的修饰的非对称抗体及使用方法
ES2978917T3 (es) 2013-07-09 2024-09-23 Annexon Inc Anticuerpos anti-factor del complemento C1q y usos de los mismos
TWI648401B (zh) * 2013-07-31 2019-01-21 安美基公司 生長分化因子１５（ｇｄｆ－１５）構築體
EP3038644B1 (en) 2013-08-28 2021-04-07 AbbVie Stemcentrx LLC Site-specific antibody conjugation methods and compositions
AU2014332458B2 (en) * 2013-09-05 2020-03-12 Igm Biosciences, Inc. Constant chain modified bispecific, penta- and hexavalent Ig-M antibodies
KR20160044060A (ko) 2013-10-11 2016-04-22 에프. 호프만-라 로슈 아게 다중특이적 도메인 교환된 통상의 가변 경쇄 항체
WO2015069794A2 (en) 2013-11-06 2015-05-14 Stem Centrx, Inc. Novel anti-claudin antibodies and methods of use
PE20160993A1 (es) 2013-12-12 2016-10-14 Abbvie Stemcentrx Llc Nuevos anticuerpos anti-dpep3 y metodos de uso
LT3083680T (lt) 2013-12-20 2020-04-10 F. Hoffmann-La Roche Ag Humanizuoti anti-tau(ps422) antikūnai ir jų naudojimo būdai
EP3089996B1 (en) 2014-01-03 2021-07-28 F. Hoffmann-La Roche AG Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
BR112016015589A2 (pt) 2014-01-06 2017-10-31 Hoffmann La Roche módulos de trânsito monovalentes para a barreira hematoencefálica
EP3835318A1 (en) 2014-01-15 2021-06-16 F. Hoffmann-La Roche AG Fc-region variants with modified fcrn- and maintained protein a-binding properties
WO2015127407A1 (en) 2014-02-21 2015-08-27 Stemcentrx, Inc. Anti-dll3 antibodies and drug conjugates for use in melanoma
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
KR102376287B1 (ko) 2014-04-02 2022-03-17 에프. 호프만-라 로슈 아게 다중특이적 항체 경쇄 잘못짝짓기의 검출 방법
JP6868394B2 (ja) * 2014-05-16 2021-05-12 ファイザー・インク 二重特異性抗体
BR112016027888A2 (pt) 2014-05-28 2017-10-24 Zymeworks Inc construto de polipeptídeo de ligação ao antígeno isolado, polinucleotídeo isolado ou um conjunto de polinucleotídeos isolados, vetor ou conjunto de vetores, célula isolada, composição farmacêutica, uso do construto, método para tratar um sujeito com uma doença ou distúrbio, método para obter um construto, método para preparar um construto, meio de armazenamento legível por computador, método para produzir um construto de polipeptídeo de ligação com antígeno bi-específico e método para preparar um construto de polipeptídeo de ligação com antígeno isolado
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
WO2015197736A1 (en) 2014-06-26 2015-12-30 F. Hoffmann-La Roche Ag Anti-brdu antibodies and methods of use
FI3177643T5 (fi) 2014-08-04 2023-11-28 Hoffmann La Roche T-soluja aktivoivia bispesifisiä antigeeniä sitovia molekyylejä
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
WO2016054315A1 (en) 2014-10-01 2016-04-07 Medimmune, Llc Method of conjugating a polypeptide
CA2963692A1 (en) 2014-10-09 2016-04-14 Engmab Ag Bispecific antibodies against cd3epsilon and ror1
CN107207587B (zh) * 2014-11-05 2022-04-19 安尼艾克松股份有限公司 人源化抗-补体因子c1q抗体及其应用
EP3215524B1 (en) 2014-11-06 2021-01-13 F.Hoffmann-La Roche Ag Fc-region variants with modified fcrn- and protein a-binding properties
BR112017006178A2 (pt) 2014-11-06 2018-05-02 F. Hoffmann-La Roche Ag região fc, anticorpos, formulação farmacêutica e usos dos anticorpos
WO2016079076A1 (en) 2014-11-20 2016-05-26 F. Hoffmann-La Roche Ag T cell activating bispecific antigen binding molecules agiant folr1 and cd3
EP3747905A1 (en) 2014-11-20 2020-12-09 F. Hoffmann-La Roche AG Common light chains and methods of use
DK3221355T3 (da) 2014-11-20 2020-12-07 Hoffmann La Roche Kombinationsbehandling med T-celleaktiverende bispecifikke antigenbindende molekyler CD3 og folatreceptor 1 (FolR1) samt PD-1-aksebindende antagonister
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
CN107001482B (zh) 2014-12-03 2021-06-15 豪夫迈·罗氏有限公司 多特异性抗体
IL253180B2 (en) * 2015-01-02 2023-04-01 Dyax Corp Bispecific antibodies against plasma kallikrein and factor xii
CN104628851B (zh) * 2015-02-12 2019-07-30 长春百克生物科技股份公司 一种抗狂犬病毒的基因工程抗体、其制备方法和应用
WO2016207245A1 (en) 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Humanized anti-tau(ps422) antibodies and methods of use
WO2017004149A1 (en) * 2015-06-30 2017-01-05 Boehringer Ingelheim International Gmbh Multi-specific binding proteins
EA201890272A1 (ru) 2015-07-10 2018-08-31 Генмаб А/С Axl-специфические конъюгаты антитело-лекарственное средство для лечения рака
BR112018001202A2 (pt) 2015-07-21 2018-09-25 Dyax Corp anticorpo monoclonal, ácido nucleico, vetor, célula hospedeira, composição farmacêutica e método
JP6622396B2 (ja) 2015-08-26 2019-12-18 バイソン セラピュイティクス インコーポレイテッド 多重特異性抗体プラットフォームおよびその関連方法
CN106519024A (zh) * 2015-09-15 2017-03-22 三生国健药业（上海）股份有限公司 一种用于去除单克隆抗体中异构体的复性液及复性方法
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
MA43028B1 (fr) 2015-10-02 2021-09-30 Hoffmann La Roche Anticorps bispécifiques pour pd1 et tim3
EP3356417A1 (en) 2015-10-02 2018-08-08 H. Hoffnabb-La Roche Ag Bispecific t cell activating antigen binding molecules binding mesothelin and cd3
WO2017055393A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
WO2017055385A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
WO2017055392A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
JP6734919B2 (ja) 2015-10-02 2020-08-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 同時結合を測定するための細胞ベースのｆｒｅｔアッセイ法
EP3150637A1 (en) 2015-10-02 2017-04-05 F. Hoffmann-La Roche AG Multispecific antibodies
US20180282410A1 (en) 2015-10-02 2018-10-04 Hoffmann-La Roche Inc. Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
EP3356410B1 (en) 2015-10-02 2021-10-20 F. Hoffmann-La Roche AG Bispecific anti-ceaxcd3 t cell activating antigen binding molecules
EP3356407B1 (en) 2015-10-02 2021-11-03 F. Hoffmann-La Roche AG Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
EP3356409A2 (en) 2015-10-02 2018-08-08 H. Hoffnabb-La Roche Ag Bispecific t cell activating antigen binding molecules
CN116396393A (zh) 2015-10-08 2023-07-07 酵活英属哥伦比亚省公司 包含κ和λ轻链的抗原结合多肽构建体及其用途
IL295756A (en) 2015-10-29 2022-10-01 Hoffmann La Roche Anti-variant fc-region antibodies and methods of use
SG11201803703UA (en) 2015-11-24 2018-06-28 Annexon Inc Anti-complement factor c1q fab fragments and uses thereof
CN108884158A (zh) 2015-12-01 2018-11-23 根马布有限公司 抗死亡受体抗体及其使用方法
US20180271998A1 (en) 2015-12-04 2018-09-27 Merrimack Pharmaceuticals, Inc. Disulfide-stabilized fabs
ES2901794T3 (es) 2015-12-09 2022-03-23 Hoffmann La Roche Anticuerpo anti-CD20 de tipo II para reducir la formación de anticuerpos antifármaco
EP3178848A1 (en) 2015-12-09 2017-06-14 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
WO2017110980A1 (ja) 2015-12-25 2017-06-29 中外製薬株式会社 増強された活性を有する抗体及びその改変方法
PL3400246T3 (pl) 2016-01-08 2021-03-08 F. Hoffmann-La Roche Ag Sposoby leczenia nowotworów z dodatnim markerem cea z wykorzystaniem antagonistów wiążących oś pd-1 oraz przeciwciał dwuswoistych anty-cea/anty-cd3
JP6991978B2 (ja) 2016-01-27 2022-02-03 メディミューン，エルエルシー 定められるグリコシル化パターンを有する抗体を調製するための方法
JP7082604B2 (ja) 2016-03-21 2022-06-08 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性および多機能性分子ならびにその使用
DK3433280T5 (da) 2016-03-22 2024-09-16 Hoffmann La Roche Protease-aktiverede T-celle-bispecifikke molekyler
CA3019524A1 (en) 2016-05-02 2017-11-09 F. Hoffmann-La Roche Ag The contorsbody - a single chain target binder
AR108377A1 (es) 2016-05-06 2018-08-15 Medimmune Llc Proteínas de unión biespecíficas y sus usos
CA3025162A1 (en) * 2016-05-26 2017-11-30 Qilu Puget Sound Biotherapeutics Corporation Mixtures of antibodies
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
TW201902512A (zh) 2016-06-02 2019-01-16 瑞士商赫孚孟拉羅股份公司 治療方法
EP3478717B1 (en) 2016-07-04 2022-01-05 F. Hoffmann-La Roche AG Novel antibody format
CN109906232B (zh) * 2016-09-23 2023-11-07 马伦戈治疗公司 包含λ轻链和κ轻链的多特异性抗体分子
CN109843926B (zh) 2016-09-30 2023-01-20 豪夫迈·罗氏有限公司 针对cd3的双特异性抗体
EP3519820B1 (en) 2016-09-30 2020-12-09 H. Hoffnabb-La Roche Ag Spr-based dual-binding assay for the functional analysis of multispecific molecules
AU2017345454B2 (en) 2016-10-19 2024-10-31 Invenra Inc. Antibody constructs
JP7277363B2 (ja) 2016-11-01 2023-05-18 ジェンマブ ビー．ブイ． ポリペプチド変異体およびその使用
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
BR112019015900A2 (pt) 2017-02-10 2020-04-07 Genmab B.V. polipeptídeo, métodos para aumentar a atividade agonística de um polipeptídeo, para aumentar a atividade de cdc de um polipeptídeo e de tratamento de um indivíduo tendo uma doença, composição, kit de partes, e, uso de um polipeptídeo ou uma composição
US20200291089A1 (en) 2017-02-16 2020-09-17 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
JP7116736B2 (ja) * 2017-03-02 2022-08-10 ノバルティス アーゲー 操作されたヘテロ二量体タンパク質
RU2750721C2 (ru) 2017-03-10 2021-07-01 Ф. Хоффманн-Ля Рош Аг Способ получения мультиспецифических антител
JP2020511988A (ja) * 2017-03-31 2020-04-23 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー シンセカイン組成物及び使用方法
KR102706161B1 (ko) 2017-03-31 2024-09-19 젠맵 홀딩 비.브이. 이중특이적 항-cd37 항체, 모노클로날 항-cd37 항체 및 그의 사용 방법
SG11201909205YA (en) 2017-04-03 2019-11-28 Hoffmann La Roche Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
CN110494452B (zh) 2017-04-03 2023-08-25 豪夫迈·罗氏有限公司 结合steap-1的抗体
JP7148539B2 (ja) 2017-04-03 2022-10-05 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 免疫抱合体
CN110506059B (zh) 2017-04-05 2023-01-17 豪夫迈·罗氏有限公司 特异性结合pd1和lag3的双特异性抗体
EP3609537A1 (en) 2017-04-13 2020-02-19 H. Hoffnabb-La Roche Ag An interleukin-2 immunoconjugate, a cd40 agonist, and optionally a pd-1 axis binding antagonist for use in methods of treating cancer
AR111963A1 (es) 2017-05-26 2019-09-04 Univ California Método y moléculas
JP2020522254A (ja) 2017-05-31 2020-07-30 エルスター セラピューティクス， インコーポレイテッド 骨髄増殖性白血病（ｍｐｌ）タンパク質に結合する多特異性分子およびその使用
EP3635005A1 (en) 2017-06-07 2020-04-15 Genmab B.V. Therapeutic antibodies based on mutated igg hexamers
UY37758A (es) 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
RU2019142330A (ru) 2017-06-30 2021-07-30 Займворкс, Инк. Стабилизированные химерные fab
AR112603A1 (es) 2017-07-10 2019-11-20 Lilly Co Eli Anticuerpos biespecíficos inhibidores de punto de control
WO2019014912A1 (zh) * 2017-07-21 2019-01-24 赵磊 一种异二聚体蛋白及其制备方法
KR20200041897A (ko) * 2017-08-01 2020-04-22 에이비 스튜디오 인코포레이티드 이중특이 항체 및 그의 용도
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
MA50667A (fr) * 2017-09-29 2020-08-05 Chugai Pharmaceutical Co Ltd Molécule multispécifique de liaison à l'antigène ayant une activité de substitution de la fonction de cofacteur du facteur viii de coagulation sanguine (fviii), et formulation pharmaceutique contenant ladite molécule en tant que principe actif
BR112020007154A2 (pt) 2017-10-20 2020-09-29 F. Hoffmann-La Roche Ag método para produzir um polipeptídeo e polipeptídeos heterodimérico
CA3078676A1 (en) 2017-10-30 2019-05-09 F. Hoffmann-La Roche Ag Method for in vivo generation of multispecific antibodies from monospecific antibodies
JP2021500902A (ja) 2017-11-01 2021-01-14 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 新規ｔｎｆファミリーリガンド三量体含有抗原結合分子
TWI829658B (zh) 2017-11-01 2024-01-21 瑞士商赫孚孟拉羅股份公司 雙特異性2+1康特斯體(Contorsbody)
CN111295392A (zh) 2017-11-01 2020-06-16 豪夫迈·罗氏有限公司 Compbody–多价靶结合物
BR112020008031A2 (pt) 2017-11-01 2020-10-27 F. Hoffmann-La Roche Ag anticorpo multiespecíficos, método para a preparação do anticorpo multiespecífico, conjunto de ácidos nucleicos, vetor de expressão, célula hospedeira e composição farmacêutica
TWI805665B (zh) 2017-12-21 2023-06-21 瑞士商赫孚孟拉羅股份公司 結合hla-a2/wt1之抗體
EP3728327A1 (en) 2017-12-22 2020-10-28 F. Hoffmann-La Roche AG Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography
WO2019145455A1 (en) 2018-01-24 2019-08-01 Genmab B.V. Polypeptide variants and uses thereof
CA3088355A1 (en) 2018-02-06 2019-08-15 F. Hoffmann-La Roche Ag Treatment of ophthalmologic diseases
CR20200391A (es) 2018-02-08 2020-10-19 Genentech Inc Moléculas biespecíficas de unión al antígeno y métodos de uso
TWI829667B (zh) 2018-02-09 2024-01-21 瑞士商赫孚孟拉羅股份公司 結合gprc5d之抗體
WO2019178364A2 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
US11845784B2 (en) 2018-04-17 2023-12-19 Heidelberg Biotech Gmbh Means and methods for the treatment of angiogenesis-, fibrosis- and cancer-related diseases with protein oligomers comprising NC-1-Fc
EP3781204A4 (en) * 2018-04-17 2022-03-30 Invenra, Inc. BINDING MOLECULES
AR114789A1 (es) 2018-04-18 2020-10-14 Hoffmann La Roche Anticuerpos anti-hla-g y uso de los mismos
AR115052A1 (es) 2018-04-18 2020-11-25 Hoffmann La Roche Anticuerpos multiespecíficos y utilización de los mismos
WO2019211472A1 (en) 2018-05-03 2019-11-07 Genmab B.V. Antibody variant combinations and uses thereof
MA52632A (fr) 2018-05-16 2021-09-15 Janssen Biotech Inc Anticorps bispécifiques bcma/cd3 et gprdc5d/cd3 aux fins d'utilisation dans le traitement du cancer
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
JP7513530B2 (ja) 2018-06-22 2024-07-09 ジェンマブ ホールディング ビー．ブイ． 抗ｃｄ３７抗体および抗ｃｄ２０抗体、組成物、ならびにそれらの使用方法
JP7554742B2 (ja) 2018-07-03 2024-09-20 マレンゴ・セラピューティクス，インコーポレーテッド 抗ｔｃｒ抗体分子およびその使用
TW202019518A (zh) 2018-07-13 2020-06-01 丹麥商珍美寶股份有限公司 Ｃｄ３８抗體之變體及其用途
WO2020012038A1 (en) 2018-07-13 2020-01-16 Genmab A/S Trogocytosis-mediated therapy using cd38 antibodies
CA3115163A1 (en) 2018-10-04 2020-04-09 Genmab Holding B.V. Pharmaceutical compositions comprising bispecific anti-cd37 antibodies
EP3870331A1 (en) * 2018-10-25 2021-09-01 F. Hoffmann-La Roche AG Modification of antibody fcrn binding
MY195550A (en) 2018-10-29 2023-01-31 Hoffmann La Roche Antibody Formulation
BR112021008774A2 (pt) 2018-11-06 2021-11-30 BioNTech SE Formulação farmacêutica, agente de ligação, métodos para tratamento de uma doença, para produzir uma formulação farmacêutica, para induzir a morte celular ou inibir o crescimento e/ou a proliferação de uma célula tumoral, e, uso de uma formulação farmacêutica
AU2019392711A1 (en) 2018-12-05 2021-05-20 Morphosys Ag Multispecific antigen-binding molecules
TWI829831B (zh) 2018-12-21 2024-01-21 瑞士商赫孚孟拉羅股份公司 結合cd3之抗體
EP3674316A1 (en) 2018-12-24 2020-07-01 Sanofi Multispecific binding proteins with mutant fab domains
PH12021500028A1 (en) 2018-12-24 2022-05-02 Sanofi Sa Pseudofab-based multispecific binding proteins
MX2021007672A (es) 2018-12-24 2021-09-30 Sanofi Sa Proteinas de union multiespecificas con dominios fab mutantes.
EP3674319A1 (en) 2018-12-24 2020-07-01 Sanofi Pseudofab-based multispecific binding proteins
EP3902560A1 (en) 2018-12-28 2021-11-03 F. Hoffmann-La Roche AG A peptide-mhc-i-antibody fusion protein for therapeutic use in a patient with amplified immune response
CA3125316A1 (en) 2018-12-28 2020-07-02 Kyowa Kirin Co., Ltd. Bispecific antibody binding to tfr
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
SG11202109033XA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
CN114026122B (zh) 2019-02-21 2024-12-31 马伦戈治疗公司 结合t细胞相关癌细胞的多功能分子及其用途
CA3131016A1 (en) 2019-02-21 2020-08-27 Andreas Loew Multifunctional molecules that bind to calreticulin and uses thereof
CA3130508A1 (en) 2019-02-21 2020-08-27 Marengo Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
CN114126714A (zh) 2019-02-21 2022-03-01 马伦戈治疗公司 抗tcr抗体分子及其用途
JP7249432B2 (ja) 2019-03-29 2023-03-30 エフ． ホフマン－ラ ロシュ アーゲー 多価分子の機能分析のための、ｓｐｒをベースとする結合アッセイ
EP3947440A1 (en) 2019-03-29 2022-02-09 F. Hoffmann-La Roche AG Method for generating avid-binding multispecific antibodies
JP2022530045A (ja) 2019-04-25 2022-06-27 エフ．ホフマン－ラ ロシュ アーゲー ポリペプチド鎖の交換により活性化される治療用多重特異性ポリペプチド
MX2021012931A (es) 2019-04-25 2021-11-17 Hoffmann La Roche Polipeptidos multiespecificos activables y terapeuticos con semivida extendida.
EP3959244A1 (en) 2019-04-25 2022-03-02 F. Hoffmann-La Roche AG Generation of antibody-derived polypeptides by polypeptide chain exchange
WO2020225456A1 (en) 2019-05-09 2020-11-12 Genmab B.V. Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer
JP7273195B2 (ja) 2019-05-13 2023-05-12 エフ． ホフマン－ラ ロシュ アーゲー 干渉抑制薬物動態イムノアッセイ
CN118547004A (zh) 2019-06-19 2024-08-27 豪夫迈·罗氏有限公司 通过使用Cre mRNA进行的靶向整合来产生蛋白质表达细胞的方法
KR20220016957A (ko) 2019-06-26 2022-02-10 에프. 호프만-라 로슈 아게 Sirt-1 유전자 녹아웃을 갖는 포유류 세포주
CN114051500A (zh) 2019-07-02 2022-02-15 豪夫迈·罗氏有限公司 包含白细胞介素-2突变体和抗cd8抗体的免疫缀合物
AR119393A1 (es) 2019-07-15 2021-12-15 Hoffmann La Roche Anticuerpos que se unen a nkg2d
CN114375302B (zh) 2019-07-26 2024-12-24 詹森生物科技公司 包含激肽释放酶相关肽酶2抗原结合结构域的蛋白质及其用途
EP4004045A1 (en) 2019-07-31 2022-06-01 F. Hoffmann-La Roche AG Antibodies binding to gprc5d
SG11202112491WA (en) 2019-07-31 2021-12-30 Hoffmann La Roche Antibodies binding to gprc5d
TW202120537A (zh) 2019-08-15 2021-06-01 美商健生生物科技公司 用於經改善的單鏈可變片段之材料及方法
US20210077697A1 (en) * 2019-09-12 2021-03-18 Fresenius Medical Care Deutschland Gmbh System and method for connecting a concentrate container with a blood treatment device without leakages
US20220411529A1 (en) 2019-11-06 2022-12-29 Genmab B.V. Antibody variant combinations and uses thereof
EP4076663A1 (en) 2019-12-18 2022-10-26 F. Hoffmann-La Roche AG Bispecific anti-ccl2 antibodies
BR112022011854A2 (pt) 2019-12-18 2022-09-06 Hoffmann La Roche Anticorpos, polinucleotídeo isolado, célula hospedeira, métodos para produzir um anticorpo e para tratar uma doença, composição farmacêutica, usos do anticorpo e invenção
EP4077374A4 (en) * 2019-12-20 2023-12-27 Kisoji Biotechnology Inc. POLYPEPTIDES, PROTEIN COMPLEXES AND ASSOCIATED PRODUCTION PROCESS
TWI766512B (zh) 2020-01-02 2022-06-01 瑞士商赫孚孟拉羅股份公司 用於判定腦中的治療性抗體量之方法
WO2021138407A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
CN114980927A (zh) 2020-01-16 2022-08-30 健玛保 Cd38抗体的配制剂及其用途
JP2023512071A (ja) 2020-01-30 2023-03-23 ウモジャ バイオファーマ， インコーポレイテッド 二特異性形質導入エンハンサー
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
TW202144418A (zh) 2020-03-13 2021-12-01 美商健生生物科技公司 唾液酸結合Ｉｇ樣凝集素結合的材料及方法
CN115485028A (zh) 2020-04-15 2022-12-16 豪夫迈·罗氏有限公司 免疫缀合物
GB2612450A (en) 2020-04-24 2023-05-03 Marengo Therapeutics Inc Multifunctional molecules that bind to T cell related cancer cells and uses thereof
EP4142722A1 (en) 2020-04-30 2023-03-08 Bristol-Myers Squibb Company Methods of treating cytokine-related adverse events
IL298038A (en) 2020-05-11 2023-01-01 Hoffmann La Roche Combination therapy with modified pbmcs and an immunoconjugate
IL298444A (en) 2020-05-27 2023-01-01 Janssen Biotech Inc Proteins comprising cd3 antigen binding domains and uses thereof
EP4168445A1 (en) 2020-06-19 2023-04-26 F. Hoffmann-La Roche AG Immune activating fc domain binding molecules
WO2021255146A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and cea
CN115698084A (zh) 2020-06-19 2023-02-03 豪夫迈·罗氏有限公司 与cd3结合的抗体
TWI811703B (zh) 2020-06-19 2023-08-11 瑞士商赫孚孟拉羅股份公司 與ｃｄ３及ｃｄ１９結合之抗體
CA3185513A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and folr1
JP2023534726A (ja) 2020-07-23 2023-08-10 ジェンマブ ビー．ブイ． 多発性骨髄腫の治療に使用するための抗ｄｒ５抗体と免疫調節イミド薬との併用
MX2023001256A (es) 2020-07-29 2023-05-16 Janssen Biotech Inc Proteínas que comprenden dominios de unión al antígeno hla-g y sus usos.
CA3190766A1 (en) 2020-08-26 2022-03-03 Marengo Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
KR20230074487A (ko) 2020-08-26 2023-05-30 마렝고 테라퓨틱스, 인크. Trbc1 또는 trbc2를 검출하는 방법
WO2022046920A2 (en) 2020-08-26 2022-03-03 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
MX2023003328A (es) 2020-09-24 2023-03-27 Hoffmann La Roche Lineas de celulas de mamifero con desactivacion genica.
JP2023547329A (ja) 2020-10-02 2023-11-10 ジェンマブ エー／エス Ｒｏｒ２へと結合することができる抗体ならびにｒｏｒ２およびｃｄ３に結合する二重特異性抗体
IL301956A (en) * 2020-10-07 2023-06-01 Dren Bio Inc Anti-dectin-1 antibodies and methods of use thereof
KR20230086765A (ko) 2020-10-13 2023-06-15 얀센 바이오테크 인코포레이티드 분화 클러스터 iv 및/또는 viii을 조절하기 위한 바이오-조작된 t 세포 매개 면역, 물질 및 기타 방법
US20240025992A1 (en) 2020-10-22 2024-01-25 Janssen Biotech, Inc. Proteins comprising delta-like ligand 3 (dll3) antigen binding domains and their uses
US20240010748A1 (en) 2020-11-10 2024-01-11 Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. Bispecific antibody for claudin 18a2 and cd3 and application of bispecific antibody
AU2021379598A1 (en) * 2020-11-10 2023-06-08 Amgen Inc. Novel linkers of multispecific antigen binding domains
WO2022104367A1 (en) * 2020-11-12 2022-05-19 Northwestern University Cell-free expression of antibodies, antigen-binding fragments thereof, and antibody derivatives
CN114539413A (zh) * 2020-11-25 2022-05-27 三生国健药业（上海）股份有限公司 结合her2的多价双特异性抗体、其制备方法和用途
US20220213199A1 (en) 2020-12-17 2022-07-07 Hoffmann-La Roche Inc. Anti-HLA-G antibodies and use thereof
EP4263595A1 (en) 2020-12-18 2023-10-25 F. Hoffmann-La Roche AG Precursor proteins and kit for targeted therapy
JP2024501662A (ja) 2020-12-22 2024-01-15 エフ． ホフマン－ラ ロシュ アーゲー Ｘｂｐ１を標的とするオリゴヌクレオチド
IL304067A (en) 2021-01-06 2023-08-01 Hoffmann La Roche Combination therapy employing a pd1-lag3 bispecific antibody and a cd20 t cell bispecific antibody
WO2022148853A1 (en) 2021-01-11 2022-07-14 F. Hoffmann-La Roche Ag Immunoconjugates
WO2022170305A1 (en) * 2021-02-05 2022-08-11 Phanes Therapeutics, Inc. Bispecific antibodies with charge pairs and uses thereof
EP4295154A1 (en) 2021-02-18 2023-12-27 F. Hoffmann-La Roche AG Method for resolving complex, multistep antibody interactions
JP2024510777A (ja) 2021-03-24 2024-03-11 ヤンセン バイオテツク，インコーポレーテツド Ｃｄ３抗原結合ドメインを含むタンパク質及びその使用
WO2022201052A1 (en) 2021-03-24 2022-09-29 Janssen Biotech, Inc. Antibody targeting cd22 and cd79b
CA3237992A1 (en) 2021-03-31 2022-10-06 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Truncated taci polypeptide and fusion protein and use thereof
GB2623199A (en) 2021-04-08 2024-04-10 Marengo Therapeutics Inc Multifunctional molecules binding to TCR and uses thereof
US20240182600A1 (en) * 2021-04-20 2024-06-06 Amgen Inc. Balanced Charge Distribution in Electrostatic Steering of Chain Pairing in Multi-specific and Monovalent IgG Molecule Assembly
MX2023012408A (es) 2021-04-30 2023-10-31 Hoffmann La Roche Dosis para tratamiento conjunto con anticuerpo biespecifico anti-cd20/anti-cd3 y conjugado anticuerpo farmaco anti-cd79b.
MX2023012699A (es) 2021-04-30 2023-11-21 Hoffmann La Roche Dosificacion para el tratamiento con anticuerpo biespecifico anti-cd20/anti-cd3.
TW202306990A (zh) 2021-05-12 2023-02-16 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合ｒａｎｋｌ和ｎｇｆ的抗原結合分子及其醫藥用途
MX2023013307A (es) 2021-05-14 2023-12-04 Jiangsu Hengrui Pharmaceuticals Co Ltd Molecula de union a antigeno.
CN117500829A (zh) 2021-06-18 2024-02-02 豪夫迈·罗氏有限公司 双特异性抗ccl2抗体
EP4363449A2 (en) 2021-07-02 2024-05-08 Genentech, Inc. Methods and compositions for treating cancer
MX2024000501A (es) 2021-07-14 2024-01-31 Jiangsu Hengrui Pharmaceuticals Co Ltd Molecula de union a antigeno que se une especificamente a hgfr y egfr, y su uso farmaceutico.
CA3219606A1 (en) 2021-07-22 2023-01-26 F. Hoffmann-La Roche Ag Heterodimeric fc domain antibodies
CN117715939A (zh) 2021-07-27 2024-03-15 莫佛塞斯公司 抗原结合分子的组合
JP2024527977A (ja) 2021-07-27 2024-07-26 ノヴァブ， インコーポレイテッド 免疫エフェクター機能を有する操作されたｖｌｒｂ抗体
IL309120A (en) 2021-07-28 2024-02-01 Hoffmann La Roche Methods and compositions for the treatment of cancer
EP4399227A1 (en) 2021-09-06 2024-07-17 Genmab A/S Antibodies capable of binding to cd27, variants thereof and uses thereof
EP4402171A1 (en) 2021-09-13 2024-07-24 Janssen Biotech, Inc. Cd33 x v delta 2 multispecific antibodies for the treatment of cancer
CN117813323A (zh) 2021-09-23 2024-04-02 江苏恒瑞医药股份有限公司 抗klb抗体及用途
EP4405392A1 (en) 2021-09-24 2024-07-31 Janssen Biotech, Inc. Proteins comprising cd20 binding domains, and uses thereof
KR20240067099A (ko) 2021-09-30 2024-05-16 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 항-il23 항체 융합 단백질 및 용도
MX2024004451A (es) 2021-10-14 2024-05-08 Hoffmann La Roche Nuevos inmunoconjugados de interleucina-7.
WO2023062048A1 (en) 2021-10-14 2023-04-20 F. Hoffmann-La Roche Ag Alternative pd1-il7v immunoconjugates for the treatment of cancer
CA3237357A1 (en) 2021-11-03 2023-05-11 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies
EP4429765A1 (en) 2021-11-10 2024-09-18 Astrazeneca AB Antibody molecules and conjugates
AU2022392829A1 (en) 2021-11-22 2024-07-11 Janssen Biotech, Inc. Compositions comprising enhanced multispecific binding agents for an immune response
EP4437344A1 (en) 2021-11-25 2024-10-02 F. Hoffmann-La Roche AG Quantification of low amounts of antibody sideproducts
AR127887A1 (es) 2021-12-10 2024-03-06 Hoffmann La Roche Anticuerpos que se unen a cd3 y plap
EP4477669A1 (en) 2022-02-07 2024-12-18 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Antigen-binding molecule specifically binding to psma and cd3, and pharmaceutical use thereof
MX2024009715A (es) 2022-02-11 2024-08-19 Jiangsu Hengrui Pharmaceuticals Co Ltd Inmunoconjugado y su uso del mismo.
KR20240161961A (ko) 2022-03-14 2024-11-13 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Gprc5d 및 cd3에 특이적으로 결합하는 항원 결합 분자 및 이의 의약적 용도
KR20240159618A (ko) 2022-03-17 2024-11-05 아스트라제네카 아베 이중특이적 항체의 정제 방법
EP4496631A1 (en) 2022-03-23 2025-01-29 F. Hoffmann-La Roche AG Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
CN119013300A (zh) 2022-04-13 2024-11-22 豪夫迈·罗氏有限公司 抗cd20/抗cd3双特异性抗体的药物组合物和使用方法
WO2023202967A1 (en) 2022-04-19 2023-10-26 F. Hoffmann-La Roche Ag Improved production cells
WO2023218051A1 (en) 2022-05-12 2023-11-16 Genmab A/S Binding agents capable of binding to cd27 in combination therapy
AU2023269545A1 (en) 2022-05-12 2024-11-14 BioNTech SE Binding agents capable of binding to cd27 in combination therapy
WO2023232961A1 (en) 2022-06-03 2023-12-07 F. Hoffmann-La Roche Ag Improved production cells
AU2023287212A1 (en) 2022-06-23 2024-12-19 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Antigen-binding molecule specifically binding to dll3 and cd3, and pharmaceutical use thereof
CN119421895A (zh) 2022-06-27 2025-02-11 阿斯利康(瑞典)有限公司 涉及用于治疗癌症的表皮生长因子受体酪氨酸激酶抑制剂的组合
WO2024017371A1 (zh) * 2022-07-22 2024-01-25 信达生物制药(苏州)有限公司 促进多特异性抗体的重链和轻链同源配对的突变体
TW202412859A (zh) 2022-07-28 2024-04-01 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物及雙特異性檢查點抑制劑之組合
CN117820490A (zh) * 2022-09-28 2024-04-05 科兴生物制药股份有限公司 Vegf和ang-2双特异性抗体及其应用
TW202430211A (zh) 2022-10-10 2024-08-01 瑞士商赫孚孟拉羅股份公司 Ｇｐｒｃ５ｄ ｔｃｂ及ｉｍｉｄ之組合療法
TW202423970A (zh) 2022-10-10 2024-06-16 瑞士商赫孚孟拉羅股份公司 Ｇｐｒｃ５ｄ ｔｃｂ及ｃｄ３８抗體之組合療法
TW202423969A (zh) 2022-10-10 2024-06-16 瑞士商赫孚孟拉羅股份公司 Ｇｐｒｃ５ｄ ｔｃｂ及蛋白酶體抑制劑之組合療法
WO2024079069A1 (en) 2022-10-12 2024-04-18 F. Hoffmann-La Roche Ag Method for classifying cells
TW202432177A (zh) 2022-10-31 2024-08-16 丹麥商珍美寶股份有限公司 Ｃｄ３８抗體及其用途
WO2024095173A1 (en) 2022-11-02 2024-05-10 Janssen Biotech, Inc. Methods of treating cancers
WO2024100170A1 (en) 2022-11-11 2024-05-16 F. Hoffmann-La Roche Ag Antibodies binding to hla-a*02/foxp3
US20240190978A1 (en) 2022-11-15 2024-06-13 CSBioAsset LLC Compositions and methods for immunomodulatory bifunctional fusion molecules
WO2024104933A1 (en) 2022-11-15 2024-05-23 F. Hoffmann-La Roche Ag Antigen binding molecules
WO2024104988A1 (en) 2022-11-15 2024-05-23 F. Hoffmann-La Roche Ag Recombinant binding proteins with activatable effector domain
TW202444751A (zh) 2023-01-20 2024-11-16 瑞士商赫孚孟拉羅股份公司 重組Ｆｃ域—ＩＬ２變異體多肽及與膜錨定抗原結合多肽的組合療法
WO2024156672A1 (en) 2023-01-25 2024-08-02 F. Hoffmann-La Roche Ag Antibodies binding to csf1r and cd3
TW202436339A (zh) 2023-01-31 2024-09-16 瑞士商赫孚孟拉羅股份公司 治療選自非小細胞肺癌或三陰性乳癌的癌症之用途
WO2024163009A1 (en) 2023-01-31 2024-08-08 Genentech, Inc. Methods and compositions for treating urothelial bladder cancer
WO2024184287A1 (en) 2023-03-06 2024-09-12 F. Hoffmann-La Roche Ag Combination therapy of an anti-egfrviii/anti-cd3 antibody and an tumor-targeted 4-1bb agonist
WO2024188965A1 (en) 2023-03-13 2024-09-19 F. Hoffmann-La Roche Ag Combination therapy employing a pd1-lag3 bispecific antibody and an hla-g t cell bispecific antibody
WO2024208776A1 (en) 2023-04-03 2024-10-10 F. Hoffmann-La Roche Ag Agonistic split antibodies
WO2024208777A1 (en) 2023-04-03 2024-10-10 F. Hoffmann-La Roche Ag All-in-one agonistic antibodies
US20250011426A1 (en) * 2023-04-06 2025-01-09 Medimmune, Llc Engineered Antibodies
WO2024231320A1 (en) 2023-05-08 2024-11-14 F. Hoffmann-La Roche Ag Targeted interferon alpha fusion proteins and methods of use
US20240400703A1 (en) 2023-05-12 2024-12-05 Genmab A/S Antibodies capable of binding to ox40, variants thereof and uses thereof
WO2024238537A1 (en) 2023-05-16 2024-11-21 F. Hoffmann-La Roche Ag Pd-1 -regulated il-2 immunocytokine and uses thereof
WO2024263904A1 (en) 2023-06-23 2024-12-26 Genentech, Inc. Methods for treatment of liver cancer
WO2024263195A1 (en) 2023-06-23 2024-12-26 Genentech, Inc. Methods for treatment of liver cancer
WO2025021838A1 (en) 2023-07-26 2025-01-30 F. Hoffmann-La Roche Ag Antibodies binding to cd3
WO2025027511A1 (en) 2023-07-30 2025-02-06 Janssen Biotech, Inc. Molecules that bind to mutant calreticulin and uses thereof

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
EP0640094A1 (en) 1992-04-24 1995-03-01 The Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
DE4425115A1 (de) * 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Verfahren zur Modifizierung der Stabilität von Antikörpern
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
AU751659B2 (en) 1997-05-02 2002-08-22 Genentech Inc. A method for making multispecific antibodies having heteromultimeric and common components
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
PT2180007E (pt) 1998-04-20 2013-11-25 Roche Glycart Ag Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
CA2359067C (en) 1999-01-15 2017-03-14 Genentech, Inc. Polypeptide variants with altered effector function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP3031917A1 (en) 1999-04-09 2016-06-15 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
JP4668498B2 (ja) 1999-10-19 2011-04-13 協和発酵キリン株式会社 ポリペプチドの製造方法
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
ATE489395T1 (de) 2000-12-12 2010-12-15 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
AU2002307037B2 (en) 2001-04-02 2008-08-07 Biogen Idec Inc. Recombinant antibodies coexpressed with GnTIII
EP1443961B1 (en) 2001-10-25 2009-05-06 Genentech, Inc. Glycoprotein compositions
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7923029B2 (en) 2002-04-11 2011-04-12 Medimmune Llc Spray freeze dry of compositions for pulmonary administration
AU2003230908A1 (en) 2002-04-11 2003-10-27 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
WO2003087327A2 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
EP1572915A4 (en) 2002-04-11 2011-01-05 Medimmune Vaccines Inc PRESERVATION OF BIOACTIVE MATERIALS BY SPRAY DRYING
AU2003297320B8 (en) 2002-12-17 2008-02-21 Medimmune, Llc High pressure spray-dry of bioactive materials
EP1587540B1 (en) 2003-01-09 2021-09-15 MacroGenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
US20050226867A1 (en) 2003-10-08 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. IL-5R-specific antibody composition
EP2348051B1 (en) 2003-11-05 2018-12-19 Roche Glycart AG CD20 antibodies with increased fc receptor binding affinity and effector function
EP1896071B1 (en) 2005-06-30 2015-04-29 Janssen Biotech, Inc. Methods and compositions with enhanced therapeutic activity
GB0514779D0 (en) * 2005-07-19 2005-08-24 Celltech R&D Ltd Biological products
EP1957099B1 (en) 2005-11-07 2015-03-25 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
PL1999154T3 (pl) 2006-03-24 2013-03-29 Merck Patent Gmbh Skonstruowane metodami inżynierii heterodimeryczne domeny białkowe
EP2035456A1 (en) 2006-06-22 2009-03-18 Novo Nordisk A/S Production of bispecific antibodies
AU2008298904B2 (en) 2007-09-14 2014-10-16 Amgen Inc. Homogeneous antibody populations
KR101456326B1 (ko) 2009-04-07 2014-11-12 로슈 글리카트 아게 3가, 이중특이적 항체
WO2010151792A1 (en) 2009-06-26 2010-12-29 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
EP3778917A3 (en) * 2009-12-04 2021-06-09 F. Hoffmann-La Roche AG Multispecific antibodies, antibody analogs, compositions, and methods
SG181952A1 (en) * 2009-12-29 2012-07-30 Emergent Product Dev Seattle Heterodimer binding proteins and uses thereof
WO2011117653A1 (en) * 2010-03-25 2011-09-29 Ucb Pharma S.A. Disulfide stabilized dvd-lg molecules
WO2011118739A1 (ja) * 2010-03-26 2011-09-29 協和発酵キリン株式会社 新規修飾部位導入抗体および抗体フラグメント
JP6048972B2 (ja) * 2010-04-23 2016-12-21 ジェネンテック， インコーポレイテッド ヘテロ多量体タンパク質の産生
PL2606064T3 (pl) 2010-08-16 2015-07-31 Novimmune Sa Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał

Also Published As

Publication number Publication date
CN104011221B (zh) 2019-01-08
PL2794905T3 (pl) 2020-11-02
AU2012355415B2 (en) 2017-07-06
WO2013096291A3 (en) 2013-09-19
HRP20201004T1 (hr) 2020-10-16
WO2013096291A2 (en) 2013-06-27
JP2015502409A (ja) 2015-01-22
EP2794905A4 (en) 2015-11-18
HUE049457T2 (hu) 2020-09-28
ES2816078T3 (es) 2021-03-31
EP2794905A2 (en) 2014-10-29
AU2012355415A1 (en) 2014-07-17
JP6541974B2 (ja) 2019-07-10
LT2794905T (lt) 2020-07-10
SMT202000342T1 (it) 2020-07-08
EP2794905B1 (en) 2020-04-01
PT2794905T (pt) 2020-06-30
RS60499B1 (sr) 2020-08-31
US9527927B2 (en) 2016-12-27
DK2794905T3 (da) 2020-07-06
HK1203560A1 (en) 2015-10-30
CY1123079T1 (el) 2021-10-29
US20140348839A1 (en) 2014-11-27
CN104011221A (zh) 2014-08-27
CA2859667C (en) 2022-05-24
CA2859667A1 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
SI2794905T1 (sl) Modificirani polipeptidi za ogrodja bispecifičnega protitelesa
CY2023014I1 (el) Αντι il-36r αντισωματα
DK3653645T3 (da) Monoklonal interleukin-31-antistof
CO6811812A2 (es) Anticuerpo anti-b7-h3
HUE036663T2 (hu) Készítmény anti-alfa4béta7 antitesthez
HUE036664T2 (hu) Készítmény anti-alfa4béta7 antitesthez
EP2714735A4 (en) SPECIFIC ANTIBODIES OF TGF BETA
BR112014024769A2 (pt) anticorpo humanizado tau
CR20140127A (es) Anticuerpo anti-abtcr
BR112013022797A2 (pt) anticorpos anti-ctla4 humanizados
DK2847231T3 (da) Multispecifikke monoklonale antistoffer
LT2794658T (lt) Bispecifinė antikūno molekulė
EP2707392A4 (en) MONOCLONAL ANTIBODY FOR ACETYLAMANTADINE
CO6841994A2 (es) Anticuerpos
LT2742068T (lt) Nauji antikūnai prieš fosforilcholiną